Who makes Bemosuzumab?

Bemosuzumab is developed by Fujian Medical University.

What development phase is Bemosuzumab in?

Bemosuzumab is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Bemosuzumab

Fujian Medical University · FDA-approved active Small molecule Quality 1/100

At a glance

Generic name	Bemosuzumab
Sponsor	Fujian Medical University
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bemosuzumab CI brief — competitive landscape report
Bemosuzumab updates RSS · CI watch RSS
Fujian Medical University portfolio CI